BioFunding

ERC to boost EU basic research

23.01.2007

A new era in science funding has started this January with the inception of the European research Council (ERC). For the first time, the European Union will channel Euro 7.5 billion of its application-orientated research framework programme into basic research of outstanding excellence. For this year, Euro 292 million have already been earmarked for so-called ‘starting independent researcher grants’ from the Euro 54 billion budget of FP7 (2007-2013), making up one third of the annual Euro 1.25 billion budget of the ERC. In autumn, a second funding scheme termed ‘the advanced investigator grant’ will be introduced. In total, 40% of the ERC’s total budget will be channelled into biological research.

The first call, especially designed for postdoc researchers, was published at the end of December with the aim of supporting independent frontier research. “This is a signal to support not only research into applications but also to back excellent basic research”, said Prof. Ernst-Ludwig Winnacker, Secretary General of the ERC. “Up to now, little money has been allocated particularly to young researchers by the national research agencies. Furthermore, there is a lot of double work in European labs. With the ERC funds, we want to improve this”, stressed Winnacker.
The German science manager will act as an ‘interface’ between the 22 scientific experts of the ERC’s Scientific Council – which is responsible for ERC strategy, and will draft and overview the implementation of the annual working programme and the evaluation process – and an executive agency (dedicated implementation structure (DIS)/directorate S) of currently 85 staff, established by the European Commission. The agency will implement the working programme, the peer review, and the evaluation process.

Criteria for measuring scientific excellence

Currently, 19 thematic interdisciplinary panels of 10 experts each, which will be supported by up to 50 scientific referees each, will evaluate the project proposals in a 2-step procedure after pre-registration.
In the first step, a project outline (excellence, feasibility, methods) and the qualification of the principal investigator (funding ID, high impact publications, ability to initiate new lines of thinking, novelty of approaches), will be evaluated using a score, qualifying applicants with a score higher than 8 to enter phase 2. In the next step, the full proposal including an assessment of the research environment (e.g. infrastructure) and a presentation will be evaluated. The deadline for pre-proposals will be 25 April 2007. It is expected that the ERC will fund about 200 projects with Euro 100,000 to Euro 400,000 per year. The main challenge for the reviewers will be on identifying promising novel research ideas besides the research mainstream.
A similar funding mechanism has been already established by the US National Science Foundation, which supports US basic researchers (NIH-funded projects excluded) with funds of Euro 4.3 billion annually.
However, research excellence will not be the only criterion for research grants. Because the new funding mechanism is part of the European Union’s framework programme FP7 it will suffer from the same political limitations. There will, for example, not be any equal treatment of European researchers working on human embryonic stem cells, due to differences between national legislations.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/article/erc-to-boost-eu-basic-research.html

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • PROTHENA PLC (IE)18.44 USD6.84%
  • WILEX (D)3.28 EUR5.47%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • HYBRIGENICS (F)1.71 EUR-8.56%

TOP

  • WILEX (D)3.28 EUR349.3%
  • SANTHERA (CH)69.50 CHF114.8%
  • ADDEX (CH)4.21 CHF92.2%

FLOP

  • MERCK KGAA (D)63.45 EUR-51.0%
  • THROMBOGENICS (B)8.55 EUR-47.3%
  • VERONA PHARMA (UK)1.12 GBP-46.2%

TOP

  • SANTHERA (CH)69.50 CHF3410.1%
  • GW PHARMACEUTICALS (UK)415.25 GBP756.2%
  • SKYEPHARMA PLC (UK)260.00 GBP314.3%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.27 CHF-92.1%
  • THROMBOGENICS (B)8.55 EUR-72.5%

No liability assumed, Date: 21.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events